Chronic moderate to severe mitral regurgitation (MR) causes left ventricular remodeling. If left untreated, MR can result in congestive heart failure and, consequently, increased morbidity and even mortality. Accordingly, patients with this condition require timely therapy. Although conventional mitral valve (MV) surgery (repair or replacement) remains the gold standard for treating MR, a significant number of patients are considered to be at too high risk for surgery and remain on pharmacotherapy alone. In an approach similar to the open Alfieri MV repair, 1 a minimally invasive approach to MR treatment using the MitraClipÒ (Abbott Vascular, Abbott Park, IL, USA) has recently been developed to improve systolic MV leaflet coaptation. It has been reported to produce good outcomes.
1,2 The MitraClip is currently implanted using fluoroscopy and transesophageal echocardiography (TEE) for guidance. 2, 3 The accompanying images are from an 80-yr-old woman who presented for percutaneous MV repair of severe MR. The main pathology was a leaflet coaptation defect in the A2/P2 and A3/P3 regions of the MV. Using fluoroscopy and two-and three-dimensional TEE guidance, a single Mitraclip was placed in the A2/P2 region. Her severe MR was reduced to mild MR. This image is notably similar to that seen in panel E, which is an anatomic specimen from a porcine MV that shows an endothelialized Mitraclip six months after MV repair. As seen in panel F, the 2D TEE mid-esophageal four-chamber view with colour flow Doppler shows only mild residual MR after MV repair with the MitraClip. Panels C and E were reproduced, with permission, from Abbott Vascular, Abbott Park, IL, USA
